Is Neurocrine Biosciences, Inc. overvalued or undervalued?

As of 21 November 2025, the valuation grade for Neurocrine Biosciences, Inc. has moved from fair to attractive, indicating a more favorable assessment of its stock. The company appears to be undervalued, supported by a P/E ratio of 35, an EV to EBITDA of 21.72, and a robust ROCE of 30.61%. In comparison, Viatris, Inc. has a higher P/E of 44.86, while Walgreens Boots Alliance, Inc. shows a negative P/E, highlighting Neurocrine's relative valuation strength within its peer group.
Despite recent underperformance against the S&P 500, with a 3-year return of 19.88% compared to the index's 67.17%, the company's strong fundamentals suggest it may be positioned for future growth. Overall, Neurocrine's attractive valuation metrics and strong return on capital indicate it is a compelling investment opportunity.